Cochrane Review Links Some Drug Promotion With Prescribing Changes, but Evidence Has Limits

An updated Cochrane review finds that pharmaceutical promotion aimed at prescribers is associated with changes in prescribing, including more prescriptions, higher costs and, in some studies, less appropriate choices. The review assessed 93 studies, but almost all were conducted in the United States, with the remainder from the United Kingdom and Europe. The findings are therefore a reason to examine how promotional influence is managed—not proof that every interaction changes a prescription or that the measured effects apply directly to Canadian pharmacists.

What the review examined

The review, published October 9, 2026, assessed research on information and promotional strategies directed at health professionals who prescribe medicines. The authors considered such approaches as gifts or payments, promotional advertising and education, free samples, and policies intended to manage conflicts of interest. The evidence base included 82 U.S. studies and 11 from the U.K. or other European countries. The researchers searched for evidence through January 2025, so the review does not include studies published after that cutoff.

The studies did not all measure the same outcomes or use the same methods. Some examined whether prescribing aligned with evidence or guidelines; others assessed the volume or cost of medicines prescribed. The authors rated confidence in the findings differently by strategy and outcome. That matters: “promotion” is not one uniform exposure, and a result about payments should not automatically be applied to every educational meeting, sample or interaction.

What the evidence suggests—and what it does not

Across the included studies, gifts and payments from industry were linked with more prescribing and higher costs, and were probably associated with less appropriate prescribing. Promotional advertising and education may also be associated with increases in inappropriate prescribing and cost; the review found the evidence on prescription volume in this area was more supportive of an increase. Policies addressing conflicts of interest probably improved prescribing appropriateness and may have reduced the quantity prescribed. By contrast, evidence about free samples was very uncertain.

These are patterns reported in observational research, not a demonstration that a particular payment caused a particular clinical decision. Differences between clinicians, workplaces, drug markets and health systems can affect both exposure to promotion and prescribing. The review also found no eligible studies from Canada or other regions beyond the U.S., U.K. and Europe. It does not establish the size of any effect in Canadian practice, nor does it assess pharmacists’ own professional decisions as a separate population.

Why it matters to pharmacy teams

Pharmacists routinely evaluate drug information, answer questions about new products and collaborate with prescribers. A review of prescribing research cannot tell an individual pharmacist how to handle every interaction, but it reinforces the value of transparent processes that keep clinical decisions anchored in comparative evidence, patient needs and applicable professional standards. It also cautions against assuming that a presentation labelled “education” is necessarily independent of promotion.

The review is not an argument that all industry information is inaccurate or that every professional interaction is inappropriate. Rather, it supports scrutiny of the source, purpose and evidence behind a claim—and organizational safeguards where financial relationships could affect, or appear to affect, decisions.

Practice guidance for pharmacists

• When reviewing a product claim, identify the supporting evidence and compare it with independent guidelines, product monographs and relevant alternatives.
• Check whether the information is promotional, educational or both; consider who selected the content and whether financial relationships are disclosed.
• Use workplace policies for gifts, sponsored education, samples and conflict-of-interest disclosures, and apply them consistently.
• For formulary, protocol or purchasing decisions, document the clinical rationale and use a process that separates evidence review from commercial influence.
• When discussing industry-provided information with a prescriber or patient, distinguish established evidence from claims that remain uncertain.
• Interpret the review cautiously in Canada: its included evidence came from other health systems and should not be presented as a measured Canadian effect.

What research is still needed

The authors’ findings leave important questions about the scale and direction of effects in different settings. Canadian studies, research focused specifically on pharmacists, and clearer comparisons among promotional strategies would help determine which safeguards are most useful and where. Until then, the review is best used as a prompt for transparent, evidence-based processes—not as a numeric estimate of how much promotion changes Canadian prescribing.

Primary source

Cochrane evidence summary: Pharmaceutical industry information and promotional strategies aimed at prescribers